Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 5/20 | 0.60 |
| ▸ | MERTK | Q12866 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11478987 | 0.98 | HCAR3 (0.58) | HCAR3MERTKLMNAPOLBGAA | |
| SCHEMBL11461585 | 0.98 | HCAR3 (0.58) | HCAR3MERTKLMNAPOLBGAA | |
| SCHEMBL3476595 | 0.98 | HCAR3 (0.58) | HCAR3MERTKLMNAPOLBGAA | |
| SCHEMBL11465510 | 0.98 | HCAR3 (0.58) | HCAR3MERTKLMNAPOLBGAA | |
| SCHEMBL11460577 | 0.98 | HCAR3 (0.58) | HCAR3MERTKLMNAPOLBGAA | |
| SCHEMBL28691867 | 0.96 | HCAR3 (0.60) | HCAR3MERTKLMNAPOLBGAA | |
| SCHEMBL1542507 | 0.92 | HCAR3 (0.58) | HCAR3MERTKLMNALTA4HTDP1 | |
| SCHEMBL11462469 | 0.90 | HCAR3 (0.51) | HCAR3MERTKLMNAPOLBGAA | |
| SCHEMBL11462467 | 0.90 | HCAR3 (0.51) | HCAR3MERTKLMNAPOLBGAA | |
| SCHEMBL11480084 | 0.86 | HCAR3 (0.48) | HCAR3MERTKLMNAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110313158-A1 | Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-12-22 | — | — | US | claimed |
| WO-2010097815-A2 | A TWO COMPONENT RECYCLABLE HETEROGENEOUS CATALYST, PROCESS FOR PREPARATION THEREOF AND ITS USE FOR PREPARATION OF AMINES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-09-02 | — | — | WO | claimed |
| US-4227014-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | claimed |
| WO-2025086591-A1 | ROTIGOTINE PRODRUG DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 烟台药物研究所 | 2025-05-01 | — | — | WO | disclosed |
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2642994-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | Ligand Pharmaceuticals Incorporated (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20110313158-A1 | Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-12-22 | — | — | US | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010097815-A2 | A TWO COMPONENT RECYCLABLE HETEROGENEOUS CATALYST, PROCESS FOR PREPARATION THEREOF AND ITS USE FOR PREPARATION OF AMINES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | HGF, EPOR, MPL | HCAR3 2585/4885MERTK 343/4885LMNA 4611/4885 |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | HCAR3 846/4885MERTK 106/4885LMNA 3995/4885 |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | HCAR3 846/4885MERTK 106/4885LMNA 3995/4885 |
| US-20110313158-A1 | Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines | HCN2, RAC2, HCN1 | HCAR3 2694/4885MERTK 4004/4885LMNA 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.